Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 8/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23364627 | 0.90 | NAMPT (0.42) | CHRM2CHRM3EPHX2NAMPTJAK1 | |
| SCHEMBL24803195 | 0.86 | SMN1; SMN2 (0.41) | CHRM2CHRM3EPHX2NAMPTJAK1 | |
| SCHEMBL30545528 | 0.84 | CHRM2 (0.39) | CHRM2CHRM3EPHX2NAMPTVNN1 | |
| SCHEMBL18422101 | 0.84 | CHRM2 (0.42) | CHRM2CHRM3EPHX2 | |
| SCHEMBL6524626 | 0.82 | NAMPT (0.35) | CHRM2CHRM3EPHX2NAMPT | |
| SCHEMBL10241579 | 0.81 | EPHX2 (0.40) | EPHX2 | |
| SCHEMBL23410627 | 0.81 | NAMPT (0.50) | CHRM2CHRM3NAMPTJAK1VNN1 | |
| Trifluoroacetic Acid SCHEMBL1246075 | 0.81 | EPHX2 (0.38) | CHRM2CHRM3EPHX2 | |
| SCHEMBL17318782 | 0.79 | CHRM2 (0.61) | CHRM2CHRM3EPHX2NAMPTJAK1 | |
| SCHEMBL2140912 | 0.79 | CYP1A2 (0.34) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070930-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-03-12 | — | — | US | disclosed |
| EP-4696316-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042740-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4054719-B1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250388608-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| US-12384750-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12351579-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250197423-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-19 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2021105474-A1 | NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION | Facio Intellectual Property B.V. (NL) | 2021-06-03 | — | — | WO | disclosed |
| EP-3328849-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | Pfizer Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-3194397-A1 | 2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD) | Chronos Therapeutics Limited (GB) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017021805-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2016042451-A1 | 2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD) | SHIRE INTERNATIONAL GMBH (CH) | 2016-03-24 | — | — | WO | disclosed |
| EP-2331546-B1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2012-02-01 | — | — | EP | disclosed |
| EP-2331546-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | Sanofi-aventis (FR) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010067102-A1 | DIAZASPIRO [5.5] UNDECANE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC-RECEPTOR ANTAGONISTS AND BETA-ADRENORECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY DISORDERS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010018327-A1 | 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070930-A1 | RAS INHIBITORS | KRAS, NRAS, RIN1 | CHRM2 4538/4885CHRM3 4635/4885EPHX2 1934/4885 |
| US-20260042740-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4673/4885CHRM3 4565/4885EPHX2 2232/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | CHRM2 4876/4885CHRM3 4877/4885EPHX2 3536/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | CHRM2 4790/4885CHRM3 4703/4885EPHX2 2202/4885 |
| US-20250197423-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CHRM2 4885/4885CHRM3 4874/4885EPHX2 3033/4885 |
| US-20250388608-A1 | RAS INHIBITORS | KRAS, NRAS, HMGCR | CHRM2 4790/4885CHRM3 4703/4885EPHX2 2202/4885 |
| US-12384750-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CHRM2 4885/4885CHRM3 4874/4885EPHX2 3033/4885 |
| US-12351579-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | CHRM2 4878/4885CHRM3 4850/4885EPHX2 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.